PDL Biopharma Inc

NASDAQ:PDLI   3:59:57 PM EDT
2.56
-0.03 (-1.16%)
Debt Financing / Related, Earnings Announcements, Bankruptcy / Related

Pdl Biopharma Reports 2020 Third Quarter Financial Results And Sets Date To File Certificate Of Dissolution

Published: 11/11/2020 21:31 GMT
PDL BioPharma Inc (PDLI) - Pdl Biopharma Reports 2020 Third Quarter Financial Results and Sets Date to File a Certificate of Dissolution.
Pdl Biopharma Inc - As of September 30, 2020, Prior to Spin-off of Lensar, Net Assets in Liquidation Were $494.7 Million.
Pdl Biopharma Inc - Net Assets Attributable to Lensar on September 30, 2020 Were $112.4 Million.
Pdl Biopharma Inc - Plans to File a Certificate of Dissolution With State of Delaware on January 4, 2021.
Pdl Biopharma Inc - Pdl Stock is Expected to Be Delisted From Nasdaq After December 31, 2020.
Pdl Biopharma - for Two Months Ended Aug 31, Net Income Attributable to Pdl's Shareholders $0.04.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be $0.00

Next Quarter Revenue Guidance is expected to be $21.14 Million
Next Quarter EPS Guidance is expected to be $0.03

More details on our Analysts Page.